Niagen Bioscience Inc NAGE Stock Analysis
- Nasdaq
- Stock
- Market closed · opens Monday 9:30 AM ET
$2.07 down $0.04, 1.66% at close Nov 6
Last close · Previous close $2.11
- Market cap
- At the Nov 6 close
- P/E ratio
- 11.50On last 12 months’ EPS
- Diluted EPS
- $0.18Last 12 months
- Dividend yield
- NoneLast 12 months
Price chart
$2.07down $0.04, 1.66%Fri, Nov 6 session
Use the left and right arrow keys to move along the chart.
Price data
Trading
- Previous close$2.11Nov 5
- Volume601.52KNov 6 session
Shares traded on all US exchanges in the last completed session. Live intraday volume covers IEX only, so it is left out.
- Avg. volume541.57KLast 21 sessions
The average daily shares traded over the last 21 trading sessions, about one calendar month.
- 52-week range: $2.04 to $7.28; now $2.07
The lowest and highest trades over the past 52 weeks, adjusted for splits. The marker shows the latest price.
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
Performance
Past performance, measured to the Nov 6 close. Total return includes reinvested dividends.Price change only, without dividends. Compared with the S&P 500, using SPY.
NAGE trailed the S&P 500 in all 7 periods.
| Period | NAGE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NAGE: down 23.0% S&P 500: down 5.6% | NAGE trailed the S&P 500 by 17.4 percentage points Trailed |
| 3M | NAGE: down 31.9% S&P 500: down 4.1% | NAGE trailed the S&P 500 by 27.8 percentage points Trailed |
| YTD | NAGE: down 67.5% S&P 500: up 8.7% | NAGE trailed the S&P 500 by 76.2 percentage points Trailed |
| 1Y | NAGE: down 68.6% S&P 500: up 10.9% | NAGE trailed the S&P 500 by 79.5 percentage points Trailed |
| Long term | ||
| 3Y | NAGE: up 37.1% S&P 500: up 75.0% +11.1% vs +20.5% a year | NAGE trailed the S&P 500 by 37.9 percentage points Trailed |
| 5Y | NAGE: down 66.8% S&P 500: up 67.8% −19.8% vs +10.9% a year | NAGE trailed the S&P 500 by 134.6 percentage points Trailed |
| 10Y | NAGE: down 12.3% S&P 500: up 313.1% −1.3% vs +15.2% a year | NAGE trailed the S&P 500 by 325.4 percentage points Trailed |
$10,000 invested in NAGE 10 years ago (Nov 4, 2016) would be worth about $8,771 at the close on , with dividends reinvested. The same amount in the S&P 500 would be worth about $41,313.
NAGE trailed the S&P 500 in all 7 periods.
| Period | NAGE and S&P 500 | vs S&P 500 |
|---|---|---|
| Short term | ||
| 1M | NAGE: down 23.0% S&P 500: down 5.6% | NAGE trailed the S&P 500 by 17.4 percentage points Trailed |
| 3M | NAGE: down 31.9% S&P 500: down 4.3% | NAGE trailed the S&P 500 by 27.6 percentage points Trailed |
| YTD | NAGE: down 67.5% S&P 500: up 7.8% | NAGE trailed the S&P 500 by 75.3 percentage points Trailed |
| 1Y | NAGE: down 68.6% S&P 500: up 9.7% | NAGE trailed the S&P 500 by 78.3 percentage points Trailed |
| Long term | ||
| 3Y | NAGE: up 37.1% S&P 500: up 68.8% +11.1% vs +19.1% a year | NAGE trailed the S&P 500 by 31.7 percentage points Trailed |
| 5Y | NAGE: down 66.8% S&P 500: up 56.9% −19.8% vs +9.4% a year | NAGE trailed the S&P 500 by 123.7 percentage points Trailed |
| 10Y | NAGE: down 12.3% S&P 500: up 252.6% −1.3% vs +13.4% a year | NAGE trailed the S&P 500 by 264.9 percentage points Trailed |
$10,000 invested in NAGE 10 years ago (Nov 4, 2016) would be worth about $8,771 at the close on , not counting dividends. The same amount in the S&P 500 would be worth about $35,257.
All-time high
$18.74
Closing high on . Now 89.0% below that record.
Split-adjusted daily closes since Jul 15, 2008.
Stock splits
1
1-for-3 on . Share counts adjust after each split.
Valuation
Financials
Reported results, not forecasts. From company filings via Tiingo; the latest report is Q2 FY26, the quarter ended Jun 30, 2026. “Last 12 months” means the four quarters from Jul 1, 2025 to Jun 30, 2026, and balance-sheet figures are as of Jun 30, 2026.
Revenue and net income
Last 12 months, with the change from the 12 months before
- Revenue
- $129.08Mup 11.0%
- Net income
- $15.99Mdown 9.8%
- Diluted EPS
- $0.18down 14.3%
Data table
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| Q3 FY24 (Sep 30, 2024) | $25.58M | $1.88M | $0.02 |
| Q4 FY24 (Dec 31, 2024) | $29.13M | $7.18M | $0.09 |
| Q1 FY25 (Mar 31, 2025) | $30.48M | $5.06M | $0.06 |
| Q2 FY25 (Jun 30, 2025) | $31.12M | $3.61M | $0.04 |
| Q3 FY25 (Sep 30, 2025) | $33.99M | $4.58M | $0.05 |
| Q4 FY25 (Dec 31, 2025) | $33.84M | $4.13M | $0.05 |
| Q1 FY26 (Mar 31, 2026) | $31.47M | $6.32M | $0.07 |
| Q2 FY26 (Jun 30, 2026) | $29.79M | $963.00K | $0.01 |
| Period | Revenue | Net income | Diluted EPS |
|---|---|---|---|
| FY21 (Dec 31, 2021) | $67.45M | −$27.13M | −$0.40 |
| FY22 (Dec 31, 2022) | $72.05M | −$16.54M | −$0.24 |
| FY23 (Dec 31, 2023) | $83.57M | −$4.94M | −$0.07 |
| FY24 (Dec 31, 2024) | $99.60M | $8.55M | $0.11 |
| FY25 (Dec 31, 2025) | $129.42M | $17.38M | $0.20 |
Margins
- Gross 64.2%
- Operating 8.2%
- Net 12.4%
The percentages above the chart cover the last 12 months; the lines show each quarter. What margins tell you
Cash flow
- $5.67MLast 12 months
Cash from operations minus capital spending: the cash left after the business maintains and grows its assets.
FCF = Operating cash flow − Capital spendingFree cash flow - Operating cash flow$5.95MLast 12 months
- Capital spending$275.00KLast 12 months
- 4.4%Last 12 months
Free cash flow as a share of revenue, both over the last 12 months.
Shareholder returns
- $4.60MLast 12 months
Cash spent repurchasing shares, net of shares issued. Buybacks shrink the share count, so each remaining share owns more of the company.
- Dividends paid$0.00Last 12 months
- Total returned$4.60MLast 12 months
81% of free cash flow
Balance sheet
- $66.74MAs of Jun 30, 2026
Cash plus short- and long-term marketable securities on the Jun 30, 2026 balance sheet.
- Total debt$2.33MAs of Jun 30, 2026
- Net cash$64.41MAs of Jun 30, 2026
- 6.50As of Jun 30, 2026
Current assets divided by current liabilities on the Jun 30, 2026 balance sheet. Above 1 means short-term assets cover the bills due within a year.
Current ratio = Current assets ÷ Current liabilitiesCurrent ratio - 0.03As of Jun 30, 2026
Total debt divided by shareholders’ equity on the Jun 30, 2026 balance sheet: a measure of financial leverage.
D/E = Total debt ÷ Shareholders’ equityDebt-to-equity ratio
Financial strength
- 5 of 9Last 12 months
vs the 12 beforeA 0–9 checklist from accounting professor Joseph Piotroski. Each test compares the last 12 months with the 12 months before and scores a point if it passes. 8–9 is strong; 0–2 is weak.
- ✓Net income was positive: passed
- ✓Operating cash flow was positive: passed
- ✗Return on assets improved: not passed
- ✗Operating cash flow exceeded net income: not passed
- ✓Long-term debt fell relative to assets: passed
- ✓Current ratio improved: passed
- ✗Share count didn’t rise: not passed
- ✓Gross margin improved: passed
- ✗Asset turnover (revenue ÷ assets) improved: not passed
- 20.5%Last 12 months
Over the last 12 months, Niagen Bioscience’s net income was 20.5% of its shareholders’ equity (averaged over the last four quarter-ends). It describes the past year, not an expected return.
ROE = Net income (last 12 months) ÷ Average equityReturn on equity - 15.0%Last 12 months
Over the last 12 months, Niagen Bioscience’s net income was 15.0% of its total assets (averaged over the last four quarter-ends): what the business earned on everything it owns.
ROA = Net income (last 12 months) ÷ Average total assets
About Niagen Bioscience Inc
Niagen Bioscience is a global bioscience company dedicated to healthy aging. The Niagen Bioscience team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that is a key regulator of cellular metabolism and is found in every cell of the human body. NAD+ levels in humans have been shown to decline with age, among other factors, and may be increased through supplementation with NAD+ precursors. Niagen Bioscience is the innovator behind the NAD+ precursor nicotinamide riboside chloride (“NRC” commonly referred to as “NR”), commercialized as the flagship ingredient Niagen®, available in both food and pharmaceutical grades. Nicotinamide riboside chloride and other NAD+ precursors are protected by Niagen Bioscience’s patent portfolio. The Company delivers Niagen® as the sole or principal dietary ingredient in its consumer product line Tru Niagen® available at www.TruNiagen.com and through partnerships with global retailers and distributors. The Company also develops and commercializes proprietary-based ingredient technologies, including food-grade Niagen® and pharmaceutical-grade Niagen®, and supplies these ingredients as raw materials to the manufacturers of consumer products and U.S. FDA-registered 503B outsourcing facilities, respectively. The Company further offers natural product fine chemicals, known as phytochemicals, and related research and development services.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- California, USA
- SEC filings
- EDGAR (opens in a new tab)
- Exchange
- Nasdaq
- Asset type
- Common stock
- Price history since
NAGE news
Explore more stocks
Prices are from the last refresh. Open any stock for its live dashboard.
Popular stocks
NAGE stock FAQ
What is NAGE stock’s price today?
Niagen Bioscience (NAGE) traded at $2.07 at the close on , down $0.04 (1.66%) from the previous close of $2.11. Over the past 52 weeks it has traded between $2.04 and $7.28.
If you invested $1,000 in NAGE 10 years ago, how much would you have now?
With dividends reinvested, $1,000 invested in NAGE on would be worth about $877 at the close on , a total return of −12.3%. The same $1,000 would be worth $332 if invested five years ago and $314 if invested one year ago. Past performance doesn’t predict future returns.
What is NAGE’s P/E ratio?
NAGE trades at 11.5 times its diluted earnings over the four quarters to ($0.18 per share), at the close. (How the P/E ratio works.)
How much revenue does Niagen Bioscience make?
Niagen Bioscience reported $129.1 million of revenue over the four quarters to , up 11.0% from the twelve months before. In its latest quarter (Q2 FY26, ended ) revenue was $29.8 million, down 4.3% from a year earlier.
Is Niagen Bioscience profitable?
Yes. Niagen Bioscience earned $16.0 million of net income over the four quarters to , a net margin of 12.4%, and its operating margin was 8.2% (what margins tell you).
What are NAGE’s earnings per share?
NAGE’s diluted earnings per share were $0.18 over the four quarters to , compared with $0.21 in the twelve months before. The latest quarter (Q2 FY26) brought $0.01 per share, against $0.04 a year earlier (how EPS works).
Does NAGE pay a dividend?
Niagen Bioscience hasn’t paid a dividend in the last twelve months.
What is NAGE’s 52-week high and low?
Over the past 52 weeks NAGE has traded as low as $2.04 and as high as $7.28. At $2.07 at the close on , it is 71.6% below that high and 1.7% above the low.
What is NAGE’s all-time high?
NAGE’s highest closing price was $18.74 on , adjusted for stock splits. At $2.07 at the close on , it is 89.0% below that record.
Has NAGE stock ever split?
Yes, once: 1-for-3 on .
How has NAGE stock performed?
Including dividends and measured to the close on , NAGE has returned −67.5% so far this year and −68.6% over the past year, and −66.8% over five years (−19.8% a year). Over the same periods the S&P 500, measured by SPY, returned +8.7%, +10.9% and +67.8%. Past performance doesn’t predict future returns.
What sector and industry is Niagen Bioscience in?
Niagen Bioscience is in the Healthcare sector and the Biotechnology industry, and is headquartered in California, USA.
What exchange does NAGE trade on?
Niagen Bioscience trades on the Nasdaq under the ticker symbol NAGE. Its price history on this dashboard begins on .
Member SIPC.Low CommissionsLearn More (opens in a new tab)Sponsored. Affiliate link: I may earn a commission. The inclusion of Interactive Brokers’ (IBKR) name, logo or weblink is present pursuant to an advertising arrangement only. IBKR is not a contributor, reviewer, provider or sponsor of content published on this site, and is not responsible for the accuracy of any products or services discussed.
About this data. Data sourced by Tiingo (opens in a new tab). The live price is Tiingo’s real-time price, based on IEX trades and quotes; intraday charts show IEX trades, and volume figures are consolidated totals for completed sessions. Prices are split-adjusted, and total returns assume dividends are reinvested. Financials come from company filings and can lag new reports. Times are Eastern.
This page is for education, not investment advice. Past performance doesn't predict future returns. Logos provided by Logo.dev (opens in a new tab).
The Interactive Brokers word and logo are trademarks of Interactive Brokers LLC (or its subsidiaries) in the US and/or elsewhere. All rights reserved.